Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GEN1046 |
Trade Name | |
Synonyms | GEN-1046|GEN 1046|DuoBody-PD-L1x4-1BB|BNT 311 |
Drug Descriptions |
GEN1046 is a bispecific antibody that binds to and simultaneously targets PD-L1 and TNFRSF9 (4-1BB), potentially resulting in T-cell activation leading to increased anti-tumor immune response and decreased tumor growth (PMID: 35176764). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | C172194 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
GEN1046 | GEN1046 | 0 | 2 |
GEN1046 + Pembrolizumab | GEN1046 Pembrolizumab | 0 | 3 |